Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02945280 · ClinicalTrials.gov registry record · Phase 4
Apixaban for Routine Management of Upper Extremity Deep Venous Thrombosis
A Phase 4 study, sponsored by Intermountain Health Care.
- Terminated
- Registry status
- Phase 4
- Development phase
- 52
- Enrollment target
NCT02945280 is a Phase 4 study that was terminated before completion, run by Intermountain Health Care. The registered enrollment target is 52 participants.
The verdict
NCT02945280, a Phase 4 study, was terminated before completion, sponsored by Intermountain Health Care.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 52 participants
- Enrollment target
Study Summary
This study will assess the safety and effectiveness of a drug called apixaban for the treatment of upper extremity deep vein thrombosis (UEDVT) and clinically important bleeding. Subjects will receive apixaban 10 mg by mouth twice a day for 7 days, followed by 5 mg by mouth twice a day for a duration of 11 weeks. There will be a followup visit at 12 weeks for all participants. A total of 375 are to be enrolled. The study drug has been approved to treat blood clots. The study drug has not been studied uniquely for the treatment of blood clots in the upper extremity however. Because it is unknown whether it is effective to treat blood clots in the upper extremity, the principal investigator cannot guarantee that there will be benefit to study subjects; however, it is hoped that the information obtained from this research study will help treat patients in the future.
Interventions
- DRUG apixaban
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2017-02-22 |
| Est. Completion | 2021-11-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02945280
The ClinicalTrials.gov registry entry for NCT02945280 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Intermountain Health Care, which has 85 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which apixaban is the first listed.
NCT02945280 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02945280 about?
NCT02945280 is a clinical study titled "Apixaban for Routine Management of Upper Extremity Deep Venous Thrombosis". This study will assess the safety and effectiveness of a drug called apixaban for the treatment of upper extremity deep vein thrombosis (UEDVT) and clinically important bleeding. Subjects will receive apixaban 10 mg by mouth twice a day for 7 days, followed by 5 mg by mouth twice a day for a duratio...
What is the current status of trial NCT02945280?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 52 participants. The study started on 2017-02-22. Estimated completion is 2021-11-11.
What interventions are being tested in trial NCT02945280?
The interventions under investigation include: apixaban (DRUG).
Who is sponsoring clinical trial NCT02945280?
This trial is sponsored by Intermountain Health Care, which has 85 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.